Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. more
Time Frame | ARVN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.23% | -2.12% | -3% |
1-Month Return | -18.55% | -3.42% | -0.73% |
3-Month Return | -27.9% | -11.13% | 2.87% |
6-Month Return | -26.96% | -5.74% | 7.17% |
1-Year Return | -49.3% | 3.97% | 25.31% |
3-Year Return | -75.36% | 1.05% | 28.38% |
5-Year Return | -53.45% | 34.37% | 81.89% |
10-Year Return | 15.14% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 42.98M | 21.80M | 46.70M | 131.40M | 78.50M | [{"date":"2019-12-31","value":32.71,"profit":true},{"date":"2020-12-31","value":16.59,"profit":true},{"date":"2021-12-31","value":35.54,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.74,"profit":true}] |
Cost of Revenue | - | - | 6.00M | 8.20M | 6.70M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":73.17,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":81.71,"profit":true}] |
Gross Profit | 42.98M | 21.80M | 46.70M | 131.40M | 78.50M | [{"date":"2019-12-31","value":32.71,"profit":true},{"date":"2020-12-31","value":16.59,"profit":true},{"date":"2021-12-31","value":35.54,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.74,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 94.50M | 146.66M | 242.00M | 394.60M | 480.00M | [{"date":"2019-12-31","value":19.69,"profit":true},{"date":"2020-12-31","value":30.55,"profit":true},{"date":"2021-12-31","value":50.42,"profit":true},{"date":"2022-12-31","value":82.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (51.52M) | (124.86M) | (195.30M) | (263.20M) | (401.50M) | [{"date":"2019-12-31","value":-5152451400,"profit":false},{"date":"2020-12-31","value":-12485747700,"profit":false},{"date":"2021-12-31","value":-19530000000,"profit":false},{"date":"2022-12-31","value":-26320000000,"profit":false},{"date":"2023-12-31","value":-40150000000,"profit":false}] |
Total Non-Operating Income/Expense | (14.30M) | 9.05M | 6.10M | 24.40M | 69.90M | [{"date":"2019-12-31","value":-20.45,"profit":false},{"date":"2020-12-31","value":12.94,"profit":true},{"date":"2021-12-31","value":8.73,"profit":true},{"date":"2022-12-31","value":34.91,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (70.29M) | (119.33M) | (191.00M) | (251.00M) | (363.90M) | [{"date":"2019-12-31","value":-7029222700,"profit":false},{"date":"2020-12-31","value":-11933206400,"profit":false},{"date":"2021-12-31","value":-19100000000,"profit":false},{"date":"2022-12-31","value":-25100000000,"profit":false},{"date":"2023-12-31","value":-36390000000,"profit":false}] |
Income Taxes | (8.16M) | (7.55M) | (7.80M) | 20.90M | 900.00K | [{"date":"2019-12-31","value":-39.04,"profit":false},{"date":"2020-12-31","value":-36.1,"profit":false},{"date":"2021-12-31","value":-37.32,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":4.31,"profit":true}] |
Income After Taxes | (62.13M) | (111.79M) | (183.20M) | (271.90M) | (364.80M) | [{"date":"2019-12-31","value":-6213203800,"profit":false},{"date":"2020-12-31","value":-11178670600,"profit":false},{"date":"2021-12-31","value":-18320000000,"profit":false},{"date":"2022-12-31","value":-27190000000,"profit":false},{"date":"2023-12-31","value":-36480000000,"profit":false}] |
Income From Continuous Operations | (70.29M) | (119.33M) | (191.00M) | (282.50M) | (295.40M) | [{"date":"2019-12-31","value":-7029222700,"profit":false},{"date":"2020-12-31","value":-11933206400,"profit":false},{"date":"2021-12-31","value":-19100000000,"profit":false},{"date":"2022-12-31","value":-28250000000,"profit":false},{"date":"2023-12-31","value":-29540000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (62.13M) | (111.79M) | (183.20M) | (271.90M) | (367.30M) | [{"date":"2019-12-31","value":-6213203800,"profit":false},{"date":"2020-12-31","value":-11178670600,"profit":false},{"date":"2021-12-31","value":-18320000000,"profit":false},{"date":"2022-12-31","value":-27190000000,"profit":false},{"date":"2023-12-31","value":-36730000000,"profit":false}] |
EPS (Diluted) | (1.36) | (2.99) | (3.81) | (5.32) | (6.50) | [{"date":"2019-12-31","value":-136,"profit":false},{"date":"2020-12-31","value":-299,"profit":false},{"date":"2021-12-31","value":-381,"profit":false},{"date":"2022-12-31","value":-532,"profit":false},{"date":"2023-12-31","value":-650,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ARVN | |
---|---|
Cash Ratio | 4.07 |
Current Ratio | 4.17 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ARVN | |
---|---|
ROA (LTM) | -20.07% |
ROE (LTM) | -59.16% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ARVN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.50 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.50 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ARVN | |
---|---|
Trailing PE | NM |
Forward PE | 17.70 |
P/S (TTM) | 7.60 |
P/B | 2.18 |
Price/FCF | NM |
EV/R | 0.98 |
EV/Ebitda | NM |
Arvinas Inc (ARVN) share price today is $18.48
Yes, Indians can buy shares of Arvinas Inc (ARVN) on Vested. To buy Arvinas Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ARVN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Arvinas Inc (ARVN) via the Vested app. You can start investing in Arvinas Inc (ARVN) with a minimum investment of $1.
You can invest in shares of Arvinas Inc (ARVN) via Vested in three simple steps:
The 52-week high price of Arvinas Inc (ARVN) is $53.08. The 52-week low price of Arvinas Inc (ARVN) is $17.37.
The price-to-earnings (P/E) ratio of Arvinas Inc (ARVN) is
The price-to-book (P/B) ratio of Arvinas Inc (ARVN) is 2.18
The dividend yield of Arvinas Inc (ARVN) is 0.00%
The market capitalization of Arvinas Inc (ARVN) is $1.23B
The stock symbol (or ticker) of Arvinas Inc is ARVN